PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 18, 20250 citationsOpen Access

Supplemental Table S3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

View Full Paper
FMFunda Meric‐BernstamMGMartin GutierrezESEnrique Sanz‐García

Key Points

  • The study focuses on drug exposure and follow-up duration for zilovertamab vedotin.
  • Participants included individuals diagnosed with metastatic solid tumors.
  • The follow-up duration was essential to assess the ongoing effects of the treatment.
  • Understanding this data may guide future treatment protocols for metastatic tumors.

Abstract

Supplemental Table S3. Study Drug Exposure and Follow-Up Duration

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Meric‐Bernstam et al. (2025) studied this question.

synapsesocial.com/papers/68d462b631b076d99fa61adehttps://doi.org/10.1158/2767-9764.30146490
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplemental Table S2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
  2. 2Supplemental Table S1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
  3. 3Supplemental Table S4 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
  4. 4Supplemental Table S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
  5. 5Table 2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025